CO2018010359A2 - Constructos de alfavirus vivo atenuado y métodos y usos de los mismos - Google Patents

Constructos de alfavirus vivo atenuado y métodos y usos de los mismos

Info

Publication number
CO2018010359A2
CO2018010359A2 CONC2018/0010359A CO2018010359A CO2018010359A2 CO 2018010359 A2 CO2018010359 A2 CO 2018010359A2 CO 2018010359 A CO2018010359 A CO 2018010359A CO 2018010359 A2 CO2018010359 A2 CO 2018010359A2
Authority
CO
Colombia
Prior art keywords
live attenuated
methods
constraints
alphaviruses
attenuated alphaviruses
Prior art date
Application number
CONC2018/0010359A
Other languages
English (en)
Inventor
Timothy Duane Powell
Jill Ann Livengood
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CO2018010359A2 publication Critical patent/CO2018010359A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a alfavirus vivos atenuados que son incapaces de replicarse en células de mosquitos y de transmisión por mosquitos vectores. Otras modalidades se refieren a métodos para generar alfavirus vivos atenuados, constructos de los mismos y usos de estos alfavirus vivos atenuados en composiciones inmunogénicas. Otras modalidades se refieren a composiciones farmacéuticas que incluyen los alfavirus vivos atenuados y métodos para manufacturar estos virus vivos atenuados. Todavía otras modalidades se refieren a los usos de estas composiciones en kits para aplicaciones portátiles tales como vacunas contra la infección por alfavirus y métodos de los mismos.
CONC2018/0010359A 2016-03-31 2018-09-27 Constructos de alfavirus vivo atenuado y métodos y usos de los mismos CO2018010359A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316264P 2016-03-31 2016-03-31
PCT/US2017/024450 WO2017172698A1 (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Publications (1)

Publication Number Publication Date
CO2018010359A2 true CO2018010359A2 (es) 2018-12-14

Family

ID=58501809

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0010359A CO2018010359A2 (es) 2016-03-31 2018-09-27 Constructos de alfavirus vivo atenuado y métodos y usos de los mismos

Country Status (17)

Country Link
US (1) US20190106682A1 (es)
EP (1) EP3436062A1 (es)
JP (1) JP2019509750A (es)
KR (1) KR20180135913A (es)
CN (1) CN109195625A (es)
AU (1) AU2017241669A1 (es)
BR (1) BR112018069079A2 (es)
CA (1) CA3019536A1 (es)
CO (1) CO2018010359A2 (es)
CR (1) CR20180457A (es)
DO (1) DOP2018000209A (es)
EC (1) ECSP18081582A (es)
MX (1) MX2018011839A (es)
PE (1) PE20190178A1 (es)
PH (1) PH12018502120A1 (es)
SG (1) SG11201808479VA (es)
WO (1) WO2017172698A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019280583B2 (en) * 2018-06-06 2022-12-15 Massachusetts Institute Of Technology Circular RNA for translation in eukaryotic cells
CN110213711B (zh) * 2019-04-22 2021-06-18 腾讯科技（深圳）有限公司 一种常驻点的估计方法、装置、设备和介质
CN114561366B (zh) * 2022-03-30 2023-06-20 西南民族大学 一种山羊库布病毒分离株及其应用
CN117925540B (zh) * 2024-03-22 2024-06-18 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
CN118127077B (zh) * 2024-05-08 2024-07-16 南京农业大学三亚研究院 基于盖塔病毒骨架的嵌合甲病毒制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
MY178870A (en) * 2008-01-24 2020-10-21 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Also Published As

Publication number Publication date
PE20190178A1 (es) 2019-02-01
PH12018502120A1 (en) 2019-07-15
CA3019536A1 (en) 2017-10-05
AU2017241669A1 (en) 2018-11-22
CN109195625A (zh) 2019-01-11
ECSP18081582A (es) 2019-02-28
MX2018011839A (es) 2019-05-23
WO2017172698A1 (en) 2017-10-05
SG11201808479VA (en) 2018-10-30
DOP2018000209A (es) 2019-01-31
JP2019509750A (ja) 2019-04-11
BR112018069079A2 (pt) 2019-01-29
KR20180135913A (ko) 2018-12-21
US20190106682A1 (en) 2019-04-11
CR20180457A (es) 2019-04-09
EP3436062A1 (en) 2019-02-06

Similar Documents

Publication Publication Date Title
CO2018010359A2 (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
AR118725A2 (es) Vectores para expresión de antígenos asociados a próstata
CO2018001534A2 (es) Una composicion de vacuna arboviral
UY37563A (es) Aislados de bacillus y usos de los mismos
CL2017000987A1 (es) Partículas tipo virus modificadas de cmv
CL2017001736A1 (es) Anticuerpos anti-cd47 y uso de los mismos.
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
MX2018007627A (es) Vacuna contra el virus del zika.
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
BR112017001796A2 (pt) composições de flagelina e seus usos
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
MX2021010060A (es) Produccion de virus en huevos aviares.
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
CO2017006969A2 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado
ZA202204981B (en) Synthetic chimeric poxviruses
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
BR112015023332A2 (pt) Toxóide, composições e método relacionados
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
CO2018010357A2 (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
CL2017001722A1 (es) Un método de activación de bacterias ácido lácticas
EA201791437A1 (ru) Композиции микросфер c инкапсулированным в липиде газом и соответствующие способы